subscribeSubscribe
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
PRESS RELEASE
03 Jul 2024
Share Share
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
PRESS RELEASE
26 Jun 2024
Share Share
Dupixent® Positive Phase 3 Data in Children 1-11 with Eosinophilic Esophagitis

Dupixent® Positive Phase 3 Data in Children 1-11 with Eosinophilic Esophagitis
GLOBENEWSWIRE
26 Jun 2024
Share Share
Dupixent Recommended For EU COPD Approval By CHMP

Dupixent Recommended For EU COPD Approval By CHMP
PRESS RELEASE
31 May 2024
Share Share
Dupixent FDA Priority Review Update For COPD With Type 2 Inflammation

Dupixent FDA Priority Review Update For COPD With Type 2 Inflammation
PRESS RELEASE
30 May 2024
Share Share
J&J acquires experimental skin disorder drug for $1.25 billion

J&J acquires experimental skin disorder drug for $1.25 billion
Ben Fidler BIOPHARMADIVE
29 May 2024
Share Share
Dupixent NOTUS COPD Phase 3 Data At ATS, NEJM

Dupixent NOTUS COPD Phase 3 Data At ATS, NEJM
GLOBENEWSWIRE
20 May 2024
Share Share
FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years

FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years
PRESS RELEASE
13 May 2024
Share Share
Dupixent sBLA Priority Review For Adolescent CRSwNP

Dupixent sBLA Priority Review For Adolescent CRSwNP
GLOBENEWSWIRE
13 May 2024
Share Share
ASLAN On Eblasakimab Data In Atopic Dermatitis From TREK-DX Study

ASLAN On Eblasakimab Data In Atopic Dermatitis From TREK-DX Study
GLOBENEWSWIRE
07 May 2024
Share Share